Warehouse research firm Jefferies launched the coverage of the cannabis business Monday with a note from analyst Owen Bennett, who started reviews on nine companies, while it estimates that the offense sector will reach $ 50 billion in annual sales over the next decade vs. just $ 17 billion this year.
Bennett also said that a "realistic" bullish case could see the industry enjoying as much as $ 130 billion in revenue in 2029 thanks to power disruptive nature.
"We see a conservative industry size of over $ 50 billion by 2029 and a realistic upside-down of $ 130 billion on broader industry disturbances," he wrote. "Global winners are those who lead both medical and recreational and have a strong position in the United States. Fear of commoditization is exaggerated. Expect to see further consolidation, take more [mainstream consumer-goods companies] positions and near-time focus that shift to performance vs. headlines / capacity expectations." [1
- Aurora Cannabis Inc. ACB). Bennett gave ACB a "Buy" rating, with a price target of C $ 12.
- CannTrust Holdings Inc. (CNTTF). CannTrust was given a "Buy" rating and a price of C $ 15.
- Canopy Growth Corp. (CGC). CGC was given a "Hold" rating, with a price target of C $ 64.  Cronos Group Inc. (CRON). CRON was rated "Underperform", received a price target of C $ 17.
- Emerald Health Therapeutics (EMHTF). The Jefferies analyst gave Emerald a "Hold" rating, with a price target of $ 4.30.
- Flowr Corp. (FLWPF). This share received a "Buy" rating, with a price target of NOK. 5.70.
- Green Organic Dutchman (TGODF). The analyst rated this stock as a "buy" with a price target of $ 6.10.
- Hexo Corp. (HEXO). Bennett listed Hexo as "Underperform" and gives it a price of $ 5.60.
- OrganiGram Holdings Inc. (OGRMF). OGRMF takes a "Buy" and a price target of C $ 10.